logo

For the Inventor, By the Inventor

La Jolla, CA, United States of America

Auspex Pharmaceuticals, Inc.


USPTO Granted Patents = 76

% Expired Patents = 25.0



Trademarks = 5

Forward Citations = 346

Loading Chart...
Loading Chart...

32 inventors (with patents filed for the assignee):

goldMedal Chengzhi Zhang (38 out of 60 patents)

silverMedal Thomas George Gant (28 out of 30 patents)

bronzeMedal Sepehr Sarshar (26 out of 34 patents)

4.  Tadimeti Rao (14 out of 14 patents)

5.  Andreas Sommer (9 out of 9 patents)

6.  John Charles Arthur (9 out of 9 patents)

7.  John Carter (9 out of 17 patents)

8.  Margaret Bradbury (9 out of 9 patents)

9.  Manouchehr Shahbaz (8 out of 8 patents)

10.  David Stamler (6 out of 6 patents)

11.  Michael Huang (6 out of 9 patents)

12.  Parag Shah (3 out of 3 patents)

13.  Mayank Joshi (3 out of 5 patents)

14.  Soumen Pattanayek (3 out of 3 patents)

15.  Divyang Patel (3 out of 3 patents)


Core Competencies:
Deutetrabenazine
Pharmaceutical Formulations
Movement Disorders
Vesicular Monoamine Transporter
Dyskinesia
Cystic Fibrosis
Beta-3-Adrenoreceptor
Janus Kinase
Lipoproten-Associated Phospholipase A2
Analogs
Pharmacokinetics
Therapeutic Agents

76 patents:

1. 12599598 - Osmotic dosage forms comprising deutetrabenazine and methods of use thereof (2026-04-14),
2. 12589075 - Osmotic dosage forms comprising deutetrabenazine and methods of use thereof (2026-03-31),
3. 12502385 - Analogs of deutetrabenazine, their preparation and use (2025-12-23),
4. 12077487 - Methods of manufacturing benzoquinoline compounds (2024-09-03),
5. 12016858 - Methods for the treatment of abnormal involuntary movement disorders (2024-06-25),
6. 11813232 - Analogs of deutetrabenazine, their preparation and use (2023-11-14),
7. 11666566 - Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 (2023-06-06),
8. 11648244 - Methods for the treatment of abnormal involuntary movement disorders (2023-05-16),
9. 11564917 - Methods for the treatment of abnormal involuntary movement disorders (2023-01-31),
10. 11446291 - Methods for the treatment of abnormal involuntary movement disorders (2022-09-20),
11. 11357772 - Methods for the treatment of abnormal involuntary movement disorders (2022-06-14),
12. 11324732 - Methods for the treatment of dyskinesia in cerebral palsy (2022-05-10),
13. 11311488 - Osmotic dosage forms comprising deutetrabenazine and methods of use thereof (2022-04-26),
14. 11179386 - Analogs of deutetrabenazine, their preparation and use (2021-11-23),
15. 11033540 - Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 (2021-06-15),
Auspex Pharmaceuticals, Inc., based in La Jolla, California, specializes in the development of innovative pharmaceutical formulations aimed at treating movement disorders. The company is known for its core technology, deutetrabenazine, which targets vesicular monoamine transporters to address conditions such as dyskinesia and cystic fibrosis. Auspex is committed to advancing therapies that improve patient outcomes in complex neurological and psychiatric conditions, leveraging its expertise in pharmacology and drug formulation.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Auspex Pharmaceuticals, Inc.
76 Patents

#11 in La Jolla, CA

#1,131 in California

#4,837 in US

#9,873 in the World

La Jolla, CA (US)
La Jolla, CA, United States of America

Auspex Pharmaceuticals, Inc.

Forward Citations = 346

32 inventors:

goldMedal Chengzhi Zhang (38 out of 60 patents)

silverMedal Thomas George Gant (28 out of 30 patents)

bronzeMedal Sepehr Sarshar (26 out of 34 patents)

4.  Tadimeti Rao (14 out of 14 patents)

5.  Andreas Sommer (9 out of 9 patents)

Please report any incorrect information to [email protected]
Loading…